Emulate launches unique high-throughput organ-chip platform
Emulate has launched the AVA Emulation System, a self-contained instrument that cultures, incubates, and images up to 96 independent organ-chip samples in a single run.
The company says that AVA delivers an unprecedented magnitude of in vivo-level insights faster than animal models while cutting consumable costs four-fold and in-lab labour by half compared to current generation technologies.
“AVA gives scientists unprecedented experimental capacity with the biological depth of live human tissue—something no other platform can match,” said Jim Corbett, Chief Executive Officer at Emulate. “By combining Emulate’s proven organ-on-a-chip technology with high-throughput consumables, automated imaging, and streamlined workflows in one benchtop unit, AVA lets teams ask bigger questions earlier and move the right drug candidates forward faster.”
AVA is reportedly the first self-contained organ-on-a-chip workstation to fuse high-throughput microfluidic tissue culture, full environmental control, and real-time imaging into a single, compact benchtop unit.
With the FDA targeting animal studies to become “the exception rather than the norm,” the need for proven human models is urgent.
Emulate’s Liver-Chip S1 has already outperformed animals, according to a 2022 Communications Medicine study, showing 87% sensitivity and 100% specificity for drug-induced liver injury.
“Moving towards reduction and in some cases replacement of animal models demands both biological fidelity and throughput,” added Dr Lorna Ewart, Emulate Chief Scientific Officer. “AVA meets those dual requirements, empowering teams to rank-order lead candidates, pinpoint off-target toxicities, and advance safer therapies with unprecedented speed and confidence.”
DIANA SPENCER, Senior Digital Content Editor, DDW
